Collegium Pharmaceutical, Inc COLL
We take great care to ensure that the data presented and summarized in this overview for COLLEGIUM PHARMACEUTICAL, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding COLL
View all-
Black Rock Inc. New York, NY5.79MShares$162 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$74 Million1.45% of portfolio
-
Rubric Capital Management LP New York, NY2.35MShares$65.9 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$64 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.14MShares$60.1 Million0.15% of portfolio
-
Invesco Ltd. Atlanta, GA1.78MShares$49.8 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.66MShares$46.6 Million0.08% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.65MShares$46.1 Million0.03% of portfolio
-
State Street Corp Boston, MA1.44MShares$40.3 Million0.0% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.35MShares$37.9 Million0.15% of portfolio
Latest Institutional Activity in COLL
Top Purchases
Top Sells
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Transactions at COLL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,348
-1.63%
|
$70,440
$30.0 P/Share
|
|
Mar 07
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,504
-0.85%
|
$45,120
$30.0 P/Share
|
|
Mar 06
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,295
-2.23%
|
$98,850
$30.0 P/Share
|
|
Mar 06
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,949
-1.09%
|
$58,470
$30.0 P/Share
|
|
Mar 06
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
26,067
-19.42%
|
$729,876
$28.5 P/Share
|
|
Mar 05
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
20,000
-12.97%
|
$560,000
$28.03 P/Share
|
|
Mar 04
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
40,000
-20.6%
|
$1,120,000
$28.08 P/Share
|
|
Mar 04
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+17.08%
|
$960,000
$24.03 P/Share
|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
30,426
-7.47%
|
$912,780
$30.52 P/Share
|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,725
+16.74%
|
-
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,623
-8.64%
|
$888,690
$30.52 P/Share
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,427
+17.97%
|
-
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,897
-3.19%
|
$176,910
$30.52 P/Share
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,075
+16.51%
|
-
|
|
Feb 10
2025
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,820
+8.74%
|
-
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
34,975
-9.61%
|
$1,049,250
$30.52 P/Share
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
69,995
+16.84%
|
-
|
|
Feb 04
2025
|
Nancy Lurker Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,726
+50.0%
|
-
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
27,500
-9.73%
|
$907,500
$33.25 P/Share
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+15.79%
|
$577,500
$21.34 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 444K shares |
|---|---|
| Exercise of conversion of derivative security | 171K shares |
| Payment of exercise price or tax liability | 101K shares |
|---|---|
| Open market or private sale | 334K shares |